Welcome to our dedicated page for Argan SEC filings (Ticker: AGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Argan, Inc. (NYSE: AGX) is a Delaware corporation whose common stock is listed on the New York Stock Exchange, and it files periodic and current reports with the U.S. Securities and Exchange Commission. This SEC filings page brings together Argan’s Forms 10-K and 10-Q, as well as its frequent Form 8-K current reports, which disclose material events such as financial results, major project contracts and dividend declarations.
In its Form 8-K filings, Argan reports items like quarterly earnings releases under results of operations and financial condition, regular quarterly cash dividend announcements, and significant EPC contract awards received by subsidiaries such as Gemma Power Systems and Atlantic Projects Company. These filings also confirm key corporate details, including Argan’s state of incorporation, the AGX trading symbol and its New York Stock Exchange listing.
For investors and analysts, Argan’s annual reports on Form 10-K and quarterly reports on Form 10-Q provide more comprehensive information on segment performance, project backlog, risk factors and accounting policies, while current reports on Form 8-K highlight specific developments between reporting periods. Filings may also describe how new EPC contracts, full notices to proceed and backlog additions affect the company’s future activity.
On this page, AI-powered tools summarize lengthy SEC documents, highlight the main points from Argan’s 10-K and 10-Q filings, and explain the significance of individual 8-K items, such as dividend changes or large contract awards. Users can also review insider and executive-related filings like Form 4, along with proxy materials, to gain additional insight into Argan’s governance and equity activity.
A holder of AGX common stock has filed a notice under Rule 144 to sell 6,595 shares through Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of $2,068,918.11. The sale follows an exercise of stock options under a registered plan on 01/07/2026, paid in cash for the same number of shares.
The notice reports 13,873,410 common shares outstanding. It also lists recent sales for the same person over the past three months: 6,493 shares on 10/20/2025 for $1,911,329.25, 2,000 shares on 10/17/2025 for $584,000.00, and 4,000 shares on 01/07/2026 for $1,313,353.88. The seller represents that they are not aware of undisclosed material adverse information about the issuer.
Argan Inc. insider William Leimkuhler has filed a notice of proposed sale of common stock under Rule 144. The filing covers 17,420 shares of Argan Inc. common stock to be sold through Fidelity Brokerage Services on the NYSE, with an aggregate market value of 6,084,000 and an approximate sale date of 01/08/2026.
The shares were acquired on 01/07/2026 through a stock option exercise from the issuer, with the same date listed for payment. The notice also reports that during the past three months, Leimkuhler sold 200 securities of Argan Inc. on 12/23/2025 for gross proceeds of 67,427.47. By signing the notice, the seller represents that he is not aware of any undisclosed material adverse information about Argan Inc.
An affiliated shareholder of AGX filed a notice of proposed sale of 4,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or around 01/07/2026, with trading reported on the NYSE. The filing notes that there were 13,873,410 shares of this class outstanding.
The seller acquired 2,050 shares on 12/15/2015 via an employee stock purchase plan for cash and 1,950 shares on 01/07/2026 through the cash exercise of stock options under a registered plan. In the past three months, the same seller reported sales of 6,493 shares of common stock on 10/20/2025 for gross proceeds of 1,911,329.25 and 2,000 shares on 10/17/2025 for gross proceeds of 584,000.00.
Argan Inc. director William F. Leimkuhler reported several transactions in the company’s common stock on December 23, 2025. As trustee of the Emily K. Leimkuhler Trust, he sold 100 shares at $337.01 per share in an open-market trade. As trustee of the Elizabeth K. Leimkuhler Trust, he sold another 100 shares at $337.93 per share.
On the same date, he also made a bona fide gift of 500 shares of Argan common stock. After these transactions, the filing shows 900 shares held indirectly for each of the two trusts and 41,034 shares held directly.
Argan Inc. director Peter W. Getsinger reported a bona fide gift of 750 shares of the company’s common stock. The transaction took place on December 23, 2025 and is reported on a Form 4 as a code "G" transaction, which indicates a gift. The reported transaction price is $0, consistent with a non-sale transfer.
Following this gift, the reporting person beneficially owns 11,847 shares of Argan Inc. common stock in direct ownership form. This filing simply updates the insider’s reported holdings and does not reflect an open‑market purchase or sale.
William F. Leimkuhler filed a Rule 144 notice to sell 200 shares of Argan, Inc. common stock through Fidelity Brokerage Services LLC on 12/23/2025 on the NYSE, with an aggregate market value of $67,580.00 and 13,873,410 shares outstanding.
The shares to be sold were originally acquired in two open market purchases of 100 shares each on 10/07/2013 and 10/08/2013, both paid in cash. The filing also reports that during the past three months, Leimkuhler sold 11,802 securities of Argan, Inc. on 10/01/2025 for gross proceeds of $3,242,370.73.
By signing the notice, the seller represents that he is not aware of any material adverse, non-public information about Argan, Inc. and that any trading plan or instructions intended to satisfy Rule 10b5-1 were adopted without such undisclosed information.
Argan, Inc. director John R. Jeffrey, Jr. reported equity compensation activity involving time-based restricted stock units that converted into common stock. On 12/14/2025, 856 shares of common stock were acquired at $0 per share, bringing his directly held stake to 5,412 shares. On 12/16/2025, he acquired a further 1,844 common shares at $0, increasing his direct holdings to 7,256 shares. Footnotes explain that these issuances came from three-year time-based restricted stock unit awards granted on 12/14/2023 and 12/16/2022, with share amounts adjusted for dividends. The filing also shows 8,000 common shares held indirectly through a John R. Jeffrey, IRA, and remaining time-based restricted stock units listed as derivative securities.
Argan Inc. director James W. Quinn reported the vesting and settlement of time-based restricted stock units into common shares. On December 14, 2025, 856 common shares were acquired at an exercise price of $0, increasing his direct holdings to 5,434 shares. On December 16, 2025, he acquired a further 1,844 shares at $0, bringing his direct ownership to 7,278 shares.
The underlying awards were Time-Based Restricted Stock Units awarded on December 14, 2023 and December 16, 2022, each with a three-year vesting schedule. According to the disclosure, 833 and 1,750 shares of common stock became issuable on December 14 and December 16, 2025, respectively, with amounts adjusted for dividends. Following these transactions, Quinn also reported indirect ownership of 43,992 shares held by the James W. Quinn 2025 GRAT No.1 and continued holdings of 3,114 and 1,364 Time-Based Restricted Stock Units.
Argan Inc director Peter W. Getsinger reported that time-based restricted stock unit awards vested and converted into common stock in two transactions during December 2025.
The awards, originally granted in December 2022 and December 2023, followed three-year vesting schedules, after which shares of Argan common stock became issuable to him at an exercise price of $0.
After these transactions, he directly owned 12,597 shares of common stock and held 1,364 time-based restricted stock units as ongoing stock-based compensation.
Argan Inc. director reports vested equity awards. On 12/14/2025 and 12/16/2025, the reporting person acquired 856 and 1,844 shares of Argan Inc. common stock at a price of $0 following the exercise of derivative awards, bringing direct ownership to 19,128 common shares.
The transactions relate to time-based restricted stock units awarded on 12/14/2023 and 12/16/2022, under which 833 and 1,750 shares of common stock became issuable on the respective 2025 vesting dates, adjusted for dividends. After these settlements, the director continues to hold 3,114 and 1,364 time-based restricted stock units as derivative securities.